Featured Publications
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, Sickle CellChildHemoglobin, SickleHeptavalent Pneumococcal Conjugate VaccineHumansPneumococcal InfectionsSerogroupVaccines, ConjugateConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American childrenInvasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
Yildirim I, Lapidot R, Shaik-Dasthagirisaheb Y, Hinderstein S, Lee H, Klevens M, Grant L, Arguedas Mohs A, Cane A, Madoff L, Johnson H, Ivanof C, Burns M, Pelton S. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use. Pediatrics 2023, 153 PMID: 38087952, DOI: 10.1542/peds.2023-063039.Peer-Reviewed Original ResearchMeSH KeywordsChildHeptavalent Pneumococcal Conjugate VaccineHumansIncidenceInfantPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsInvasive pneumococcal diseaseIPD casesPCV13 eraPneumococcal diseaseCases of IPDIncidence of IPDRates of IPDPneumococcal conjugate vaccine useSerotype 15B/CImplementation of PCV13Non-PCV13 serotypesPneumococcal conjugate vaccineConfidence intervalsStatewide surveillance systemIPD incidence ratesIPD ratesPenicillin nonsusceptibilityConjugate vaccineVaccine serotypesSerotype 19ASterile sitesIncidence rateVaccine useLower incidenceVaccine formulations
2020
Recognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine
Stevens JP, Lively A, Jerris R, Yildirim I, Lantis P. Recognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine. Pediatric Emergency Care 2020, 38: e354-e359. PMID: 33181795, DOI: 10.1097/pec.0000000000002288.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccineLumbar puncturePneumococcal meningitisConjugate vaccineMeningeal signsLow suspicionMental statusPositive cerebrospinal fluid culturesLonger hospital lengthStreptococcus pneumoniae meningitisCerebrospinal fluid culturesCranial nerve palsyHours of admissionTertiary pediatric hospitalPoor clinical outcomeTertiary healthcare systemPneumococcal meningitis casesPneumococcal immunizationPneumoniae meningitisHospital lengthNerve palsyPrimary outcomeAntibiotic administrationClinical outcomesPediatric hospitalWho is at risk of 13-valent conjugated pneumococcal vaccine failure?
Yildirim M, Keskinocak P, Pelton S, Pickering L, Yildirim I. Who is at risk of 13-valent conjugated pneumococcal vaccine failure? Vaccine 2020, 38: 1671-1677. PMID: 31974018, DOI: 10.1016/j.vaccine.2019.12.060.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolHumansIncidenceInfantMassachusettsPneumococcal InfectionsPneumococcal VaccinesTreatment FailureVaccines, ConjugateConceptsInvasive pneumococcal diseaseVaccine failureIPD casesVaccine serotypesDiagnosis of IPDHigh vaccine coverage ratesPneumococcal conjugate vaccineVaccine coverage ratesUnderlying risk factorsYears of ageMonths of agePneumococcal pneumoniaImmunization PracticesVaccine scheduleConjugate vaccinePneumococcal diseasePrimary dosesClinical presentationImmunization scheduleSerotype 19ACourse of immunisationRisk factorsComorbiditiesStudy periodPassive surveillance
2018
Infants at Risk for Invasive Pneumococcal Disease in the 13-Valent Pneumococcal Conjugate Vaccine Era
Yildirim I, Pelton SI. Infants at Risk for Invasive Pneumococcal Disease in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases 2018, 69: 91-92. PMID: 30281070, DOI: 10.1093/cid/ciy848.Peer-Reviewed Original ResearchThe relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis
Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Muñoz-Almagro C, Mameli C, Kandasamy R, Lavi N, Daprai L, van der Ende A, Trzciński K, Nzenze SA, Meiring S, Foster D, Bulkow LR, Rudolph K, Valero-Rello A, Ducker S, Vestrheim DF, von Gottberg A, Pelton SI, Zuccotti G, Pollard AJ, Sanders EAM, Campbell H, Madhi SA, Nair H, Kyaw MH. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: A systematic review and meta-analysis. Journal Of Infection 2018, 77: 368-378. PMID: 29964140, DOI: 10.1016/j.jinf.2018.06.004.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive disease potentialPneumococcal conjugate vaccineNon-vaccine typesPCV introductionPneumococcal diseaseClinical syndromePneumococcal serotypesSurveillance of IPDDisease potentialSystematic reviewCurrent pneumococcal conjugate vaccinesYears of ageRandom-effects modelConjugate vaccineRoutine immunisationDisease presentationFuture vaccinesStreptococcus pneumoniaeSerotype 1SerotypesSyndromeCarriageChildrenVaccine
2017
Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness
Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, Pelton SI, T, Health H. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine 2017, 35: 4002-4009. PMID: 28645717, DOI: 10.1016/j.vaccine.2017.05.077.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineInvasive disease potentialPneumococcal diseaseLow invasive capacityInvasive capacityPCV13 eraCommon serotypesIncidence of IPDNasopharyngeal colonization ratePost-vaccine eraDisease potentialCarriage serotypesPCV eraConjugate vaccineNasopharyngeal carriageCarriage prevalencePneumococcal colonizationEnhanced surveillanceDynamic epidemiologyAge groupsSerotype 3Serotype XOlder childrenLow invasiveness
2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine
Yildirim I, Shea KM, Pelton SI. Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics Of North America 2015, 29: 679-697. PMID: 26610421, PMCID: PMC4662776, DOI: 10.1016/j.idc.2015.07.009.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccinePneumococcal diseaseConjugate vaccineOtitis mediaUniversal immunizationAcute otitis mediaInvasive pneumococcal diseaseCase fatality rateVulnerable pediatric patientsSpectrum of serotypesCause pneumoniaPediatric patientsComorbid conditionsHealthy childrenFatality rateDiseaseHost susceptibilityImmunizationVaccineHigh rateChildrenEmpyemaMastoiditisPneumoniaPatientsVaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease
Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease. Pediatrics 2015, 135: 495-503. PMID: 25647674, DOI: 10.1542/peds.2014-2426.Peer-Reviewed Original ResearchMeSH KeywordsBacterial CapsulesChildChild, PreschoolComorbidityFemaleFollow-Up StudiesHumansIncidenceInfantMaleMassachusettsPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillancePrognosisRetrospective StudiesRisk AssessmentRisk FactorsStreptococcus pneumoniaeVaccinationVaccines, ConjugateConceptsInvasive pneumococcal diseasePneumococcal diseaseUnderlying conditionOutcomes of IPDPrevention of IPDChildhood invasive pneumococcal diseasePneumococcal vaccination statusPolysaccharide pneumococcal vaccineYear of diagnosisPrimary care providersCase fatality rateChronic respiratory diseasesImmunocompromising conditionsIPD diagnosisUnderlying comorbiditiesImmunization PracticesIPD casesPneumococcal vaccineVaccination statusConjugate vaccineMassachusetts childrenClinical presentationSerotype distributionHigher hospitalizationClinical data
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchMeSH KeywordsCarrier StateChildChild, PreschoolHumansIncidenceInfantInfant, NewbornMassachusettsPneumococcal InfectionsSerotypingStreptococcus pneumoniaeConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X